About adc therapeutics sa - ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
ADCT At a Glance
ADC Therapeutics SA
Biopôle
Epalinges, Vaud 1066
| Phone | 41-212-653-02-00 | Revenue | 70.84M | |
| Industry | Pharmaceuticals: Major | Net Income | -157,846,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 1.839% | |
| Fiscal Year-end | 12 / 2025 | Employees | 265 | |
| View SEC Filings |
ADCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.729 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.514 |
| Enterprise Value to Sales | 0.924 |
| Total Debt to Enterprise Value | 1.878 |
ADCT Efficiency
| Revenue/Employee | 267,309.434 |
| Income Per Employee | -595,645.283 |
| Receivables Turnover | 3.487 |
| Total Asset Turnover | 0.209 |
ADCT Liquidity
| Current Ratio | 3.82 |
| Quick Ratio | 3.591 |
| Cash Ratio | 3.118 |
ADCT Profitability
| Gross Margin | 86.977 |
| Operating Margin | -184.443 |
| Pretax Margin | -221.917 |
| Net Margin | -222.83 |
| Return on Assets | -46.647 |
| Return on Equity | N/A |
| Return on Total Capital | 198.189 |
| Return on Invested Capital | N/A |
ADCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -154.435 |
| Total Debt to Total Assets | 38.201 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -152.713 |